NMRA

Neumora Therapeutics, Inc.

NASDAQ: NMRA · HEALTHCARE · BIOTECHNOLOGY

$1.90

-6.86% today

Updated 2026-06-05

Market cap

$302.01M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.33

Dividend yield

—

52W range

$1 – $4

Volume

1.4M

Market cap

$302.01M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.33

Dividend yield

—

52W range

$1 – $4

Volume

1.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-11.0

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$8.91

+368.95%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy5 Buy1 Hold0 Sell1 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -11.00 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-46.40M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-130.90M	$-235.93M	$-243.79M	$-236.93M	$-53.46M
EPS	—	—	—	—	$-1.33
Free cash flow	$-115.41M	$-163.40M	$-182.94M	$-206.44M	$-46.40M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NMRA	$302.01M	24	4.3	3.0	5.0	6.0	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Neumora Therapeutics, Inc. trades at $1.90. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -11.00, it sits in the distress.

Frequently asked questions

What is Neumora Therapeutics, Inc.'s stock price?

Neumora Therapeutics, Inc. (NMRA) trades at $1.90.

Is Neumora Therapeutics, Inc. overvalued?

Neumora Therapeutics, Inc. carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Neumora Therapeutics, Inc. (NMRA)?

The 12-month analyst consensus target is $8.91, about 368.9% above the current $1.90. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Neumora Therapeutics, Inc.'s Altman Z-Score is -11.00, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-314.65%

Beta3.05

50D MA$2.06

200D MA$2.20

Shares out0.19B

Float0.10B

Short ratio—

Avg volume1.4M

Performance

1 week-4.51%

1 month+6.88%

3 months+9.91%

YTD+30.17%

1 year—

3 years—

5 years—

Compare

NMRA vs LLY →NMRA vs JNJ →NMRA vs ABBV →Stock screener →